Tag: Biologie

  • Building envelope as a living CO₂ filter

    Building envelope as a living CO₂ filter

    The construction sector is considered one of the biggest sources of CO₂ emissions worldwide. Researchers at ETH Zurich are now pursuing a radically different approach. They have developed a living, organic building material that actively binds carbon dioxide from the atmosphere during its lifetime. Inside this material live cyanobacteria, also known as blue-green algae, which produce biomass via photosynthesis and also form carbon-containing minerals.

    The innovation combines biology, material science and 3D printing to create a promising concept for climate-neutral construction. The material is not only functional, but also structurally customisable. It can be moulded into freely selectable shapes, is lightweight and only requires sunlight, CO₂ and artificial seawater to grow.

    3D printing with photosynthesis in the system
    The project is led by Mark Tibbitt, Professor of Macromolecular Engineering at ETH. Together with his interdisciplinary team, he has succeeded in developing a hydrogel that stably coats the sensitive cyanobacteria and makes them printable at the same time. The result is a biologically active system that is architecturally mouldable and at the same time continuously binds CO₂.

    The double binding effect is remarkable. The material stores carbon both in the growing biomass of the bacteria and in the form of stable minerals. This creates a permanent carbon store that can potentially significantly reduce the carbon footprint of buildings.

    From the laboratory to the built environment
    The researchers see the primary area of application in the future in the building sector, for example as a façade coating. In contrast to conventional building materials, which cause emissions, this material could absorb CO₂ throughout its entire life cycle.

    Its implementation in architectural formats has already been tested at renowned platforms such as the Venice Biennale and the Triennale in Milan. The experience gained there shows that the concept can prove itself not only in the laboratory, but also in an architectural context.

    Potential for urban cycles
    The material is more than just an ecological experiment. It could become part of future urban material cycles. By not only housing users, but also serving as biological CO₂ sinks, buildings open up a new chapter in climate-conscious architecture.

    The ETH researchers’ findings have been published in the journal Nature Communications. An indication of the scientific relevance and level of innovation of the development. Now it is time to take the next steps towards scalability and long-term stability.

  • Roche opens new centre for pharmaceutical research

    Roche opens new centre for pharmaceutical research

    A significant milestone has been reached at Roche’s headquarters in Basel. The inauguration of the new Pharma Research and Early Development Centre (pRED). The centre, which offers 1,800 state-of-the-art workstations for laboratory and office work, brings together experts from various fields of research. The aim is to increase the efficiency of research and development through close collaboration. Federal Councillor Guy Parmelin also attended the opening ceremony, which emphasises the national importance of this project.

    With the new pRED Centre, Roche is pursuing a clear vision of pooling expertise from areas such as chemistry, biology and data science in order to drive forward pioneering innovations. Thomas Schinecker, CEO of the Roche Group, emphasised the central role of the centre in the company’s global innovation network. “This centre will not only improve the efficiency of our research, but also help us to achieve the greatest possible benefit for patients worldwide.”

    Investing billions in the future
    The investment in the pRED Centre is part of Roche’s long-term commitment to the Basel site. Since 2009, the company has invested 4.6 billion Swiss francs in the expansion of the site. With the new four buildings – including two high-rise laboratory buildings, an office complex and a congress centre – Roche is sending another strong signal for the future.

    And this is just the beginning: a further 1.2 billion Swiss francs are being invested in modernising and expanding the site, which will strengthen Basel’s role as a global centre for pharmaceutical research and development in the long term.

    With the opening of the new pRED Centre, Roche is not only investing in its own innovative strength, but also in strengthening Basel as a business location. This billion-euro investment is a clear signal that the pharmaceutical company intends to further expand its leading role in global research and development – a significant step both for the industry and for the region.